Angle founder and CEO steps down after shareholder backlash
Liquid biopsy company ANGLE Plc has announced the resignations of its chief executive and finance director "following feedback and discussions with a significant shareholder".
The firm, which is focused on circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, said on Friday that CEO and founder Andrew Newland, who started the company in 1994, has agreed to step down.
He will depart along with CFO Ian Griffiths, who has been at Angle since 1995.
"They remain committed and supportive of the company and intend to support the Company with an orderly handover," the company said in a short statement.
Angle's board, which now comprises just two members - non-executive chair Jan Groen and non-executive director Joseph Eid - will be expanded "in due course", the company said.
The development follows a 67% drop in Angle's share price since the start of the year and comes just three days after interim results showed a 20% drop in revenues and a 21% increase in losses in the first half.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
